This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Bupropion Sustained Release: A Therapeutic Overview

Jonathan R. T. Davidson, M.D., and Kathryn M. Connor, M.D.

Published: April 1, 1998

Article Abstract

Sustained-release bupropion (bupropion SR) represents a new form of an already known effectiveantidepressant drug. Its pharmacokinetics, mechanism of action, metabolism, and efficacy are reviewed.Benefit relative to placebo has been demonstrated in two large multicenter trials, with lowdoses (100 or 150 mg) having been shown to have therapeutic efficacy. An overview of all placebocontrolledtrials of bupropion SR is given, and the differential properties of bupropion and serotonergicdrugs are described. The concept of a catecholamine-indolamine spectrum is presented, along withits implications for possible differential therapeutics of selective antidepressants.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 59

Quick Links: